Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.

Hematological Oncology
Francesca PalandriMassimiliano Bonifacio

Abstract

Patients with myelofibrosis at intermediate-1 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require treatment. Since registrative COMFORT studies included only patients at intermediate-2/high International Prognostic Score System risk, safety and efficacy data in intermediate-1 patients are limited. We report on 70 intermediate-1 patients treated with ruxolitinib according to standard clinical practice that were evaluated for response using the 2013 IWG-MRT criteria. At 6 months, rates of spleen and symptoms response were 54.7% and 80% in 64 and 65 evaluable patients, respectively. At 3 months, ruxolitinib-induced grade 3 anemia and thrombocytopenia occurred in 40.6% and 2.9% of evaluable patients, respectively. Notably, 11 (15.9%) patients experienced at least one infectious event ≥grade 2. Most (82.6%) patients were still on therapy after a median follow-up of 27 months. These data support the need for standardized guidelines that may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and pot...Continue Reading

References

Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naseema GangatAyalew Tefferi
Mar 2, 2012·The New England Journal of Medicine·Claire HarrisonGiovanni Barosi
Mar 2, 2012·The New England Journal of Medicine·Srdan VerstovsekHagop M Kantarjian
Jun 2, 2012·British Journal of Haematology·John T ReillyUNKNOWN Writing group: British Committee for Standards in Haematology
Oct 5, 2016·American Journal of Hematology·Nicola PolverelliFrancesca Palandri
Mar 1, 2014·Therapeutic Innovation & Regulatory Science·David K RaynorDavid Bryant

❮ Previous
Next ❯

Citations

Aug 31, 2019·British Journal of Haematology·Emanuela Sant'AntonioElisa Rumi
Apr 17, 2020·Leukemia & Lymphoma·Prithviraj Bose, Srdan Verstovsek
Oct 22, 2018·Annals of Hematology·Francesca PalandriMargherita Maffioli
Sep 27, 2019·Current Fungal Infection Reports·Marissa A ZarakasMichail S Lionakis
Sep 10, 2020·HemaSphere·Prithviraj Bose, Srdan Verstovsek
Feb 10, 2018·Current Medicinal Chemistry·Felice RivelleseFrancesca Wanda Rossi
Dec 18, 2020·Expert Opinion on Drug Safety·Giacomo Coltro, Alessandro M Vannucchi
Dec 18, 2021·Blood Research·Fatma ArikanTulin Tuglular

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.